Puro Pharmaceuticals: Holding subsidiary obtains registration certificate for a suspension of oseltamivir phosphate.

Pro Pharmaceutical Industry announced that its holding subsidiary, Zhejiang Pu Lao Kangyu Pharmaceutical Co., Ltd., recently received the "Drug Registration Certificate" for the oseltamivir phosphate granules suspension issued by the National Medical Products Administration. The oseltamivir phosphate granules suspension is used for the treatment of type A and type B influenza in patients aged 2 weeks and above, and for the prevention of type A and type B influenza in individuals aged 1 year and above. According to relevant data, the oseltamivir phosphate granules suspension is estimated to have a market size of approximately 5 million bottles in China in 2024, with sales amounting to around 160 million yuan. As of the disclosure date of this announcement, the cumulative research and development expenses for the oseltamivir phosphate granules suspension amount to 8.3789 million yuan.